This agreement reinforces Lubrizol’s commitment to Make-In-India and broadens a previously committed US$ 350 million investment to support local manufacturing
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%
Growth markets revenue increased by 44 YoY to Rs. 812 crore
Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension
Q2 FY25 Total Income was at Rs. 85.4 crore
Hospital business revenues increase 13.9% to Rs. 1,655 crore
Subscribe To Our Newsletter & Stay Updated
